The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial

Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial

March 1, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The CIMPASI-1 and CIMPASI-2 trials were the first Phase 3 clinical trials conducted with certolizumab pegol (Cimzia) to treat moderate to severe chronic plaque psoriasis. These randomized, parallel-group multicenter studies were designed to evaluate the efficacy and safety of certolizumab pegol. Based on the positive results of these two studies, a third study, CIMPACT, was developed to compare the safety and efficacy of certolizumab pegol with placebo in moderate to severe chronic plaque psoriasis patients. The secondary endpoint compared the efficacy and safety of certolizumab pegol with etanercept.1

You Might Also Like
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
  • Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis
Also By This Author
  • Secukinumab Meets 5-Year Benchmark for Psoriasis

CIMPACT had a multi-center, placebo-controlled and active-controlled design. Five hundred and fifty-nine patients with moderate to severe chronic plaque psoriasis were randomized into one of four dosing arms: Group A received 400 mg certolizumab pegol every two weeks (n=167); Group B received 400 mg certolizumab pegol at Weeks 0, 2 and 4 followed by 200 mg certolizumab pegol every two weeks (n=165); Group C received 50 mg etanercept twice weekly (n=170); and Group D received placebo every two weeks (n=57).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Results
Certolizumab pegol demonstrated statistically significant improvements for the primary endpoint, with the percentage of patients achieving a 75% or greater disease improvement from baseline as measured by the Psoriasis Area and Severity Index (PASI75) compared with placebo at Week 12. At Week 12, the PASI75 response rate for Group A was 66.7%, the PASI75 response rate for Group B was 61.3% and the PASI75 response rate for Group D was 5.0%.

Additionally, certolizumab pegol achieved superiority at the 400 mg dose and non-inferiority at the 200 mg dose compared with etanercept. No new safety signals were identified.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Certolizumab pegol is not currently approved anywhere to treat plaque psoriasis. The manufacturer plans to submit marketing applications for this treatment in the third quarter of 2017.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Dermira. News release: Final Cimzia (certolizumab pegol) phase 3 trial meets primary efficacy endpoint in patients with moderate to severe chronic plaque psoriasis. 2017 Jan 18.

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Scleroderma Tagged With: Certolizumab Pegol, etanercept, plaque psoriasis

You Might Also Like:
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
  • Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis
  • Certolizumab Pegol Effective for Treating Rheumatoid Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.